Evidence map›Paper›PMID 33008777›Full record

ArticleJournal of infection and public health2020

In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2.

Sathish Kumar Chidambaram, Daoud Ali, Saud Alarifi, Surendrakumar Radhakrishnan, Idhayadhulla Akbar

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Journal of infection and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Antiviral Effects of Secondary Metabolites fromPlants (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Article
  9. Journal of tropical medicine · 2023
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Sathish Kumar ChidambaramResearch Department of Chemistry, Nehru Memorial College (Affiliated to Bharathidasan University), Puthanampatti, 621007, Tiruchirappalli District, Tamil Nadu, India.
Daoud AliDepartment of Zoology, College of Sciences, King Saud University (KSU), P.O. Box 2455, Riyadh, 11451, Saudi Arabia.
Saud AlarifiDepartment of Zoology, College of Sciences, King Saud University (KSU), P.O. Box 2455, Riyadh, 11451, Saudi Arabia.
Surendrakumar RadhakrishnanResearch Department of Chemistry, Nehru Memorial College (Affiliated to Bharathidasan University), Puthanampatti, 621007, Tiruchirappalli District, Tamil Nadu, India.
Idhayadhulla AkbarResearch Department of Chemistry, Nehru Memorial College (Affiliated to Bharathidasan University), Puthanampatti, 621007, Tiruchirappalli District, Tamil Nadu, India. Electronic address: idhayadhulla@nmc.ac.in.
Bharathidasan University · INKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe unique anthropological coronavirus which has been titled as SARS-CoV-2 was originally arisen in late 2019 in Wuhan, China affecting respiratory infection named as COVID-19. Coronavirus is disturbing human life in an exceptional method and has converted a public health global crisis. Natural products are ahead consideration due to the huge beneficial window and effective anti-inflammatory, immunomodulatory, antioxidant and antiviral possessions. Consequently, the present study was intended to display inhibition ability of natural products coumarins and their analogues against SARS coronavirus.

methodsThe present study, aims to forecast theoretical assembly for the protease of COVID-19 and to discover advance whether this protein may assist as a target for protease inhibitors such as psoralen, bergapten, imperatorin, heraclenin, heraclenol, saxalin, oxepeucedanin, angelicin, toddacoumaquinone, and aesculetin. The docking score of these natural coumarin analogues compared with standard Hydroxychloroquine. Whereas the 3D assembly of main protease of SARS coronavirus was forecast with SWISS MODEL web server, and molecular interaction studies amongst target protein and ligands were done with AutoDock Vina software.

resultsThe study more exposed that all the inhibitors acquired with negative dock energy against the target protein. Molecular docking investigation displayed that natural coumarin analogue toddacoumaquinone displayed a remarkable inhibition ability with the binding energy of -7.8 kcal/mol than other compounds against main protease of SARS coronavirus in intricate with α-ketoamide (PDB ID: 5N5O). The synthetic coumarin analogue (1 m) also displayed the comparable inhibition ability with a binding energy of -7.1 kcal/mol against main protease of SARS coronavirus in intricate with α-ketoamide. Keeping the overhead results of ADME and toxicity, all tested compounds were recognized as drug-like nature, passing Lipinski's "Rule of 5" with 0 violation except α-ketoamide passes Lipinski's "Rule of 5" with 1 violation MW > 500. The projected constraints are within the assortment of recognized values.

conclusionsBased upon the results of the manifold sequence alliance, natural and synthetic coumarin binding sites were preserved. The present in silico examination thus, delivers structural awareness about the protease of COVID-19 and molecular relations with some of the recognised protease inhibitors.

Indexed as

Molecular Docking SimulationAntiviral AgentsBetacoronavirusBinding SitesChinaCoronavirus InfectionsCoumarinsCOVID-19HumansModels, MolecularPandemicsPneumonia, ViralProtease InhibitorsSARS-CoV-2Antiviral AgentscoumarinCoumarinsProtease Inhibitors5N5O proteinCoumarinCOVID-19Molecular dockingVirtual ADME

Identifiers

PMID33008777
PMCPMC7505582
OpenAlexW3087255910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.